GlassScriptPhysician profile
Samer K Khaled
NPI 1376785006
$68,802.11
in general payments reported to CMS, 2019-2025
19 companies · $9,250 in 2025
The $9,250 reported for 2025 was more than what 88% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41K · 2020: $13K · 2021: $3,894 · 2022: $194 · 2023: $19.05 · 2024: $574 · 2025: $9,250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,520 · Food and Beverage: $1,424 · Travel and Lodging: $885 · Education: $13.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,520.00 |
| Food and Beverage | $1,424.32 |
| Travel and Lodging | $885.38 |
| Education | $13.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $29,037.06 | 2019-2020 | |
| Daiichi Sankyo INC. | $12,805.11 | 2019 | |
| Omeros Corporation | $11,363.16 | 2019-2021 | |
| Kite Pharma, INC. | $9,042.66 | 2024-2025 | Yescarta |
| Astellas Pharma US INC | $3,032.00 | 2021-2024 | Xospata |
| Novartis Pharmaceuticals Corporation | $2,743.00 | 2020-2022 | |
| Genzyme Corporation | $149.41 | 2024-2025 | |
| Janssen Biotech, INC. | $146.21 | 2025 | Rybrevant, Carvykti |
| Jazz Pharmaceuticals INC. | $129.10 | 2024 | |
| Adaptive Biotechnologies Corporation | $111.96 | 2024 | Clonoseq |
| Dexcom, INC. | $90.46 | 2022-2023 | Dexcom G6 Transmitter |
| Sobi, INC | $63.61 | 2025 | |
| Legend Biotech USA INC. | $30.56 | 2025 | Carvykti |
| Sanofi-Aventis U.S. LLC | $25.14 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $18.85 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $13.82 | 2025 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samer Khaled listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.